Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
Enoxaparin vs LOVENOX (PRESERVATIVE FREE)
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Enoxaparin is a low molecular weight heparin that binds to antithrombin III, potentiating its inhibition of factor Xa and thrombin. It has a higher ratio of anti-factor Xa to anti-factor IIa activity compared to unfractionated heparin.
Low molecular weight heparin (LMWH) that potentiates antithrombin III, accelerating inactivation of factor Xa and thrombin.
Prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement, knee replacement, or medical patients at risk,Treatment of acute DVT with or without pulmonary embolism,Treatment of unstable angina and non-ST-segment elevation myocardial infarction (NSTEMI) in combination with aspirin,Prophylaxis of ischemic complications in patients with acute ST-segment elevation myocardial infarction (STEMI) managed medically or with percutaneous coronary intervention
Prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement, knee replacement, or medical patients at risk,Treatment of DVT with or without pulmonary embolism,Prophylaxis of ischemic complications in unstable angina or non-Q-wave myocardial infarction,Treatment of acute ST-segment elevation myocardial infarction (STEMI) managed medically or with percutaneous coronary intervention
1 mg/kg subcutaneously every 12 hours for treatment of venous thromboembolism; 40 mg subcutaneously once daily for prophylaxis of venous thromboembolism.
1 mg/kg subcutaneously every 12 hours or 1.5 mg/kg subcutaneously once daily.
Terminal elimination half-life is 4.5 hours after a single subcutaneous dose, and 7 hours after repeated dosing, reflecting accumulation. Mean half-life is approximately 4-5 hours in healthy volunteers.
Terminal half-life: 3-5 hours after subcutaneous injection; prolonged in renal impairment (up to 8-10 hours with Cr Cl <30 m L/min).
Enoxaparin is primarily metabolized in the liver by desulfation and depolymerization; elimination is via renal excretion of low molecular weight fragments.
Metabolized primarily by desulfation and depolymerization in the liver via heparinases; renally eliminated as unchanged drug and metabolites.
Renal elimination accounts for 40% of the administered dose, with the remainder undergoing hepatic metabolism and/or distribution. Biliary/fecal excretion is minimal (<5%).
Renal: 40-60% as unchanged drug and low molecular weight fragments via glomerular filtration; biliary/fecal: negligible.
Enoxaparin is highly protein bound (>80%) to antithrombin III and other plasma proteins.
Approximately 90% bound to antithrombin III (minor binding to other plasma proteins).
Volume of distribution is approximately 0.15-0.25 L/kg (4-6 L total), indicating limited extravascular distribution, primarily confined to the vascular compartment.
4-7 L (0.06-0.1 L/kg) – predominantly confined to intravascular space.
Subcutaneous: Approximately 92-100% bioavailability based on anti-Xa activity. Oral: negligible due to poor absorption.
Subcutaneous: ~90-100% (almost complete absorption).
For Cr Cl <30 m L/min: reduce dose to 1 mg/kg subcutaneously once daily for treatment; for prophylaxis, reduce to 30 mg subcutaneously once daily.
For Cr Cl <30 m L/min: reduce dose to 1 mg/kg subcutaneously once daily. For Cr Cl 30-50 m L/min: no dose adjustment required, but monitor carefully.
No specific dose adjustment recommended; use with caution in severe hepatic impairment.
No specific dose adjustment recommended for hepatic impairment; caution in severe hepatic impairment due to increased bleeding risk.
For treatment of venous thromboembolism: 1 mg/kg subcutaneously every 12 hours. For prophylaxis: 0.5 mg/kg subcutaneously every 12 hours. Dose adjustments based on anti-Xa monitoring.
Neonates: 1.5 mg/kg subcutaneously every 12 hours. Infants and children: 1 mg/kg subcutaneously every 12 hours.
Increased risk of bleeding; consider lower initial doses and monitor renal function and bleeding closely. No specific dose adjustment solely based on age.
No specific dose adjustment, but increased risk of bleeding; monitor renal function and adjust dose if Cr Cl <30 m L/min.
Spinal or epidural hematomas, including subsequent paralysis, may occur in patients receiving enoxaparin who are undergoing neuraxial anesthesia or spinal puncture. Risk is increased by use of indwelling epidural catheters, concomitant use of drugs affecting hemostasis, history of traumatic or repeated epidural or spinal puncture, or spinal deformity.
Spinal/epidural hematomas, including subsequent paralysis, may occur in patients anticoagulated with LMWH or heparinoids who receive neuraxial anesthesia or undergo spinal puncture. Risk increased by use of indwelling epidural catheters, concomitant use of drugs affecting hemostasis, history of traumatic or repeated epidural/spinal punctures, or history of spinal deformity or surgery.
Increased risk of bleeding, especially in patients with renal impairment, uncontrolled hypertension, or history of gastrointestinal bleeding; thrombocytopenia (including heparin-induced thrombocytopenia); elevated serum potassium levels (hyperkalemia); use in pregnancy and lactation; elderly patients (increased bleeding risk).
Risk of bleeding; thrombocytopenia, including heparin-induced thrombocytopenia (HIT); use in renal impairment (reduce dose if Cr Cl <30 m L/min); elderly patients (increased bleeding risk); pregnancy (category B); use with caution in patients with history of heparin-induced thrombocytopenia; monitor for signs of bleeding.
Active major bleeding; history of heparin-induced thrombocytopenia (HIT); hypersensitivity to enoxaparin or heparin; patients undergoing regional anesthesia with known bleeding risk; severe uncontrolled hypertension; bacterial endocarditis; conditions with increased risk of hemorrhage (e.g., recent surgery, trauma, peptic ulcer disease, hemorrhagic stroke).
Active major bleeding; history of heparin-induced thrombocytopenia (HIT) or heparin-induced thrombocytopenia with thrombosis (HITT); hypersensitivity to heparin or pork products; not recommended for use in patients with prosthetic heart valves, especially pregnant women (risk of valve thrombosis).
No specific food interactions. Vitamin K-rich foods (leafy greens) do not significantly affect LMWH, in contrast to warfarin. Avoid excessive alcohol intake due to increased bleeding risk. Do not take supplements like fish oil, ginkgo, or ginger without consulting prescriber due to antiplatelet effects.
No known direct food interactions. However, foods high in vitamin K (e.g., green leafy vegetables, broccoli, Brussels sprouts) may theoretically affect coagulation but are not a concern with LMWH. Avoid or limit alcohol consumption due to increased bleeding risk.
Enoxaparin does not cross the placenta and is not teratogenic. No increased risk of fetal malformations has been observed in human studies. First trimester: no known risk. Second and third trimesters: no known risk, though there is a risk of maternal hemorrhage that could affect the fetus.
Low risk of teratogenicity; enoxaparin does not cross the placenta and is not associated with fetal malformations. In the first trimester, risk of teratogenicity is minimal but consider anticoagulation alternatives if VTE prophylaxis needed; second and third trimesters: no known teratogenic risk, but increased risk of maternal bleeding and placental abruption; perinatal: risk of neonatal bleeding if administered near delivery.
Enoxaparin is not detected in breast milk due to its high molecular weight and protein binding; therefore, it is considered compatible with breastfeeding. M/P ratio: not applicable (not measurable).
Excreted into breast milk in negligible amounts; M/P ratio not clinically significant; compatible with breastfeeding; no adverse effects in nursing infants reported.
Pregnancy increases clearance of enoxaparin; dose adjustments may be needed based on anti-Xa monitoring. Generally, dose adjustments are not routinely required for standard prophylactic doses, but therapeutic doses may need to be increased (e.g., weight-based dosing) and monitored. Avoid use in patients with active major bleeding or known hypersensitivity.
Dose adjustment not typically required based on pregnancy alone; however, increased plasma volume and renal clearance may necessitate dose escalation; monitor anti-Xa levels and adjust dose to maintain target range (e.g., 0.5-1.0 IU/m L for twice-daily prophylaxis); avoid dose adjustment for physiological anemia.
Enoxaparin is a low molecular weight heparin (LMWH) that preferentially inhibits factor Xa over thrombin. Monitor anti-factor Xa levels in patients with renal impairment (Cr Cl <30 m L/min) and in pregnant women. Protamine sulfate partially reverses anticoagulation (approximately 60% anti-factor Xa activity). Avoid intramuscular injections due to hematoma risk. Epidural/spinal anesthesia increases risk of spinal hematoma; remove catheter at least 12 hours after last dose (or 24 hours if therapeutic dosing). Adjust dose for moderate renal impairment (Cr Cl 30-50 m L/min) in treatment of VTE or unstable angina.
Lovenox (enoxaparin) is a low molecular weight heparin (LMWH) that does not require routine monitoring of anti-Xa levels except in special populations (e.g., renal impairment, obesity, pregnancy). Use with caution in patients with severe renal impairment (Cr Cl <30 m L/min) as enoxaparin accumulates; consider dose reduction or alternative agent. Protamine sulfate can partially reverse anticoagulation (1 mg protamine per 1 mg enoxaparin). Risk of spinal/epidural hematoma with neuraxial anesthesia or spinal puncture; remove catheter at least 12 hours after last prophylactic dose and 24 hours after last treatment dose. Contraindicated in active major bleeding, history of heparin-induced thrombocytopenia (HIT), or hypersensitivity to heparin products. Calculate dose based on actual body weight, not ideal body weight, for treatment indications.
Do not skip doses; take at the same time each day.,Rotate injection sites (left and right sides of abdomen) and do not rub the site after injection.,Watch for signs of bleeding: unusual bruising, blood in urine/stool, prolonged bleeding from cuts, or bleeding from gums.,Seek emergency care if you have signs of a spinal blood clot (back pain, numbness/weakness in legs, loss of bowel or bladder control).,Avoid aspirin, NSAIDs (ibuprofen, naproxen), and other blood thinners unless prescribed by your doctor.,Tell all healthcare providers including dentists that you are taking enoxaparin.,Do not drive or operate heavy machinery if you feel dizzy or weak from bleeding.,Store enoxaparin at room temperature; do not freeze.
Do not stop taking or change the dose without consulting your healthcare provider.,Report any signs of bleeding (unusual bruising, prolonged bleeding, blood in urine/stool, coughing up blood, bleeding gums) or injection site reactions (pain, redness, swelling).,Avoid aspirin, NSAIDs (ibuprofen, naproxen), or other blood thinners unless prescribed by your doctor.,Inform your doctor if you are pregnant, plan to become pregnant, or are breastfeeding.,If you have an epidural or spinal tap, inform your doctor that you are taking enoxaparin.,Store at room temperature; do not freeze. Use prefilled syringes only once and dispose of properly.,If you miss a dose, take it as soon as possible unless it is almost time for the next dose; do not double the dose.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about Enoxaparin vs LOVENOX (PRESERVATIVE FREE), answered by our medical review team.
Enoxaparin is a Low Molecular Weight Heparin that works by Enoxaparin is a low molecular weight heparin that binds to antithrombin III, potentiating its inhibition of factor Xa and thrombin. It has a higher ratio of anti-factor Xa to anti-factor IIa activity compared to unfractionated heparin.. LOVENOX (PRESERVATIVE FREE) is a Low Molecular Weight Heparin that works by Low molecular weight heparin (LMWH) that potentiates antithrombin III, accelerating inactivation of factor Xa and thrombin.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between Enoxaparin and LOVENOX (PRESERVATIVE FREE) depend on the specific clinical indication. These are both Low Molecular Weight Heparin agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of Enoxaparin is: 1 mg/kg subcutaneously every 12 hours for treatment of venous thromboembolism; 40 mg subcutaneously once daily for prophylaxis of venous thromboembolism.. The standard adult dose of LOVENOX (PRESERVATIVE FREE) is: 1 mg/kg subcutaneously every 12 hours or 1.5 mg/kg subcutaneously once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between Enoxaparin and LOVENOX (PRESERVATIVE FREE) in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. Enoxaparin is classified as Category A/B. Enoxaparin does not cross the placenta and is not teratogenic. No increased risk of fetal malformations has been observed in human studies. First trimester: no known risk. Second a. LOVENOX (PRESERVATIVE FREE) is classified as Category C. Low risk of teratogenicity; enoxaparin does not cross the placenta and is not associated with fetal malformations. In the first trimester, risk of teratogenicity is minimal but con. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.